Sivakumar Nagaraju, MD
Pulmonary Disease · Albuquerque, NMNPI 1952373235
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AstraZeneca at 25.2% of the total.
Across 223 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$693
- Boehringer Ingelheim$372
- Grifols USA, LLC$356
- Regeneron Healthcare Solutions, Inc.$283
- Mylan Specialty L.p.$212
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,768100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 56 | $1,204 |
| GSK | 41 | $693 |
| Boehringer Ingelheim | 16 | $372 |
| Grifols USA, LLC | 19 | $356 |
| Regeneron Healthcare Solutions, Inc. | 12 | $283 |
| Mylan Specialty L.p. | 8 | $212 |
| AbbVie(2 entities) | 10 | $180 |
| Intuitive Surgical | 2 | $170 |
| Sanofi | 7 | $135 |
| Jazz Pharmaceuticals Inc. | 5 | $125 |
| Abiomed | 1 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $103 |
| Actelion Pharmaceuticals US, Inc. | 4 | $94 |
| Pfizer | 5 | $89 |
| Viatris Specialty LLC | 4 | $81 |
| Novartis | 4 | $77 |
| Genentech USA, Inc. | 4 | $74 |
| Amgen | 3 | $57 |
| Insmed, Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $42 |
| Itamar Medical Inc | 1 | $32 |
| Johnson & Johnson | 1 | $32 |
| La Jolla Pharmaceutical Company | 1 | $31 |
| Baxter Healthcare | 2 | $29 |
| Shire North American Group Inc | 2 | $28 |
| Gilead | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $19 |
| United Therapeutics Corporation | 1 | $18 |
| Philips North America LLC | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $13 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$129
- OFEV$104
How this compares
$4,768 in reported general payments places this provider in the 85th percentile of 56 pulmonary disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 16 | $211,060 |
| Spiriva RespimatTiotropium Bromide | 127 | $67,850 |
| Dupixent PenDupilumab | 13 | $46,160 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $41,814 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $27,300 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $15,712 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $14,557 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $13,329 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $9,150 |
| Spiriva HandihalerTiotropium Bromide | 16 | $8,814 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $8,514 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 155 | $5,914 |
| Arnuity ElliptaFluticasone Furoate | 27 | $5,610 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $5,136 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $4,543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $372 | $288,060159 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $693 | $97,794179 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $1,204 | $29,04170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 56 pulmonary disease providers in New Mexico.
Other pulmonary disease in Albuquerque
- Lana Melendres GrovesAlbuquerque$1.1M
- Michelle HarkinsAlbuquerque$24K
- Viral GandhiAlbuquerque$14K
- Arjan FloraAlbuquerque$10K
- Akshay SoodAlbuquerque$9K
- Ronald BronitskyAlbuquerque$4K
- Daniel NazonAlbuquerque$2K
- Sarah MedrekAlbuquerque$2K
- James BradleyAlbuquerque$1K
- Anne BostwickAlbuquerque$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.